Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet

Full text
Author(s):
de Mendonca, Mariana [1] ; Cardoso dos Santos, Bruna de Araujo [1] ; de Sousa, Erica [1] ; Rodrigues, Alice Cristina [1]
Total Authors: 4
Affiliation:
[1] Univ Sao Paulo, Dept Pharmacol, Inst Biomed Sci, Sao Paulo, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Molecular and Cellular Endocrinology; v. 493, AUG 1 2019.
Web of Science Citations: 1
Abstract

Pioglitazone has been used for the treatment of nonalcoholic fatty liver disease (NAFLD) related to diabetes. The role of adiponectin in pioglitazone-induced improvements in NAFLD was studied by using wild-type (adipoWT) and adiponectin knockout (adipoKO) mice. High-fat diet fed mice were insulin resistant, glucose intolerant and had increased hepatic lipid accumulation as evidenced by increased NAFLD activity score. Despite pioglitazone has improved insulin resistance in both genotypes, hepatic steatosis was only improved in adipoWT obese mice. Amelioration of NAFLD in adipoWT mice promoted by pioglitazone was associated with up-regulation of Pparg, Fgf21 and down-regulation of Pepck liver expression. On the other hand, resistance to pioglitazone treatment in adipoKO mice was associated with increased expression of miR-192 and Hsl, which was not followed by increased fatty acid oxidation. In conclusion, our data provides evidence that increased adiponectin production by pioglitazone is necessary for its beneficial action on NAFLD. (AU)

FAPESP's process: 15/24650-0 - Role of microRNAs on control of adiponectin gene expression
Grantee:Mariana de Mendonça
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 15/24789-8 - MicroRNAs on adiponectin signalling: potential therapeutical targets of insulin resistance and insulin resistance linked diseases.
Grantee:Alice Cristina Rodrigues
Support type: Regular Research Grants